crimeancongo
hemorrhag
fever
cchf
viru
caus
sever
frequent
fatal
hemorrhag
diseas
peopl
mortal
rate
approxim
cchf
viru
extens
geograph
distribut
medic
import
tickborn
viral
diseas
second
widespread
medic
import
viral
hemorrhag
fever
virus
dengu
viru
describ
emerg
viru
cchf
distribut
much
asia
middl
east
africa
expand
area
southeastern
europ
continu
spread
tick
vector
reservoir
hyalomma
speci
climat
chang
modern
farm
practic
result
viru
becom
establish
territori
previous
endem
introduct
turkey
greec
recent
spain
testament
cchf
viru
recogn
possibl
agent
bioterror
iraq
studi
potenti
biolog
weapon
viru
also
shown
potenti
dissemin
via
aerosolis
recogn
antivir
compound
vaccin
proven
effect
cchf
viru
control
trial
vaccin
develop
bulgaria
use
sinc
base
cchf
viru
deriv
suckl
mous
brain
inactiv
chloroform
vaccin
elicit
cellmedi
humor
immun
multipl
dose
requir
neutralis
activ
observ
even
activ
low
date
control
efficaci
studi
vaccin
unlicens
european
medicin
agenc
us
food
drug
administr
due
crude
prepar
unlik
gain
widespread
intern
regulatori
approv
recent
vaccin
approach
cchf
includ
dnabas
vaccin
express
glycoproteinencod
region
viru
induc
neutralis
antibodi
approxim
half
vaccin
mice
anoth
vaccin
candid
use
transgen
tobacco
leav
express
cchf
viral
glycoprotein
fed
mice
induc
igg
iga
howev
neutralis
activ
test
neither
vaccin
approach
test
protect
lethal
diseas
use
challeng
model
efficaci
assess
promis
cchf
vaccin
candid
publish
date
modifi
vaccinia
ankara
mva
vector
express
fulllength
glycoprotein
induc
humor
cellular
immun
along
protect
adult
small
anim
model
cchf
viru
infect
genom
cchf
viru
distribut
rna
segment
small
medium
larg
l
encod
viral
nucleoprotein
np
glycoprotein
rna
polymeras
respect
vaccin
report
publish
date
focus
segment
compel
evid
vaccin
base
segment
would
feasibl
altern
np
recogn
predomin
antigen
induc
high
immun
respons
bunyaviru
infect
also
highli
conserv
strain
addit
np
use
antigen
target
vaccin
demonstr
protect
effect
rang
viral
diseas
tabl
particular
interest
protect
effect
np
antigen
shown
virus
bunyavirida
famili
cchf
viru
member
hantaviru
rift
valley
fever
viru
np
cchf
viru
consist
larg
globular
domain
plu
protrus
contain
conserv
cleavag
site
globular
region
respons
rna
bind
role
cleavag
site
current
unclear
shown
nucleoprotein
cleav
apoptot
cell
later
stage
infect
may
play
regulatori
role
rna
polymeras
increas
cleavag
disrupt
np
format
essenti
viru
multipl
therefor
repres
potenti
vaccin
target
report
document
incorpor
cchf
viru
segment
modifi
vaccinia
viru
ankara
mva
vector
vaccin
candid
test
immunogen
efficaci
use
murin
model
vitro
express
mvanp
construct
order
verifi
proper
express
insert
cchf
np
use
western
blot
assay
use
antibodi
ascertain
molecular
size
insert
protein
band
approxim
kda
observ
consist
estim
size
cchf
np
kda
plu
tag
tpa
region
immunogen
mvanp
effect
interferon
receptor
defici
vaccin
induc
immun
immunogen
studi
use
mous
strain
repres
suscept
cchf
host
parent
wildtyp
strain
respect
assess
whether
interferon
receptor
defici
possess
mice
affect
vaccineinduc
immun
respons
strain
mice
immunis
vaccin
observ
figur
induc
similar
number
ifng
secret
cell
specif
peptid
deriv
cchf
np
strain
mice
p
mannwhitney
statist
test
respons
tpa
tag
similarli
low
group
demonstr
specif
respons
insert
protein
furthermor
shown
figur
western
blot
analysi
reveal
mice
develop
antibodi
respons
specif
np
mice
therefor
defici
interferon
receptor
affect
induct
humor
cellmedi
immun
respons
vaccin
assay
determin
efficaci
vaccin
challeng
model
develop
infect
strain
cchf
viru
plan
therefor
develop
homolog
vaccin
np
insert
chang
equival
region
strain
ensur
new
construct
confer
similar
immun
respons
vaccin
anim
mice
vaccin
dose
separ
week
week
final
dose
anim
cull
shown
figur
npspecif
tcell
respons
detect
vaccin
anim
addit
demonstr
figur
npspecif
antibodi
detect
anim
test
therefor
taken
forward
test
efficaci
studi
efficaci
mvanp
surviv
mice
n
per
group
vaccin
dose
space
week
interv
time
point
week
final
vaccin
challeng
lethal
dose
cchf
viru
seen
figur
despit
induct
npspecif
immun
prior
challeng
mice
succumb
lethal
infect
day
postchalleng
assess
whether
vaccin
gave
reduct
viral
load
target
site
cchf
viral
replic
viral
load
analysi
use
rtpcr
conduct
blood
spleen
liver
collect
postchalleng
anim
challeng
seen
figur
observ
differ
anim
challeng
empti
vector
versu
immunis
cchf
vaccin
candid
spleen
patchi
diffus
infiltr
parenchyma
macrophag
note
primarili
involv
red
pulp
vari
degre
effac
white
pulp
tabl
addit
lymphocyt
loss
apoptosi
observ
latter
character
presenc
tingeabl
bodi
macrophag
apoptot
bodi
use
immunohistochemistri
posit
stain
cell
consist
macrophag
observ
diffus
scatter
throughout
parenchyma
primarili
within
red
pulp
liver
chang
compris
multifoc
hepatocyt
necrosi
character
cytoplasm
eosinophilia
nuclear
pyknosi
accompani
frequent
mix
inflammatori
cell
infiltr
mainli
polymorphonuclear
leukocyt
tabl
posit
stain
hepatocyt
detect
immunohistochemistri
observ
scatter
throughout
parenchyma
elicit
immun
respons
cchf
viral
np
modifi
vaccinia
viru
ankara
mva
viral
vector
use
mva
one
advanc
recombin
poxvir
vaccin
vector
use
human
clinic
trial
elicit
humor
cellular
immun
respons
latter
point
particularli
pertin
defin
correl
protect
cchf
viru
prime
arm
immun
system
may
offer
best
opportun
observ
protect
effect
result
studi
confirm
induct
antibodi
cellmedi
immun
noteworthi
bulgarian
vaccin
base
suckl
mous
brain
inactiv
chloroform
heat
c
absorb
aluminum
hydroxid
also
induc
tcell
humor
immun
efficaci
vaccin
yet
test
anim
model
studi
homolog
primeboost
approach
undertaken
demonstr
induc
increas
number
antigenspecif
cell
compar
singl
dose
data
shown
find
line
other
use
similar
approach
mvabas
vaccin
mycobacterium
tuberculosi
human
immunodefici
viru
hiv
repeat
administr
mva
allow
reboost
respons
despit
induct
cellular
humor
immun
respons
vector
report
phase
iii
therapeut
cancer
vaccin
trial
well
phase
hiv
vaccin
trial
use
np
contrast
other
opt
use
envelop
glycoprotein
candid
antigen
target
extern
locat
glycoprotein
make
favor
target
induct
neutralis
antibodi
recogn
strict
correl
vitro
neutralis
vivo
protect
cchf
virusspecif
antibodi
np
consid
appropri
vaccin
antigen
due
sever
characterist
np
bunyaviru
infect
recogn
predomin
antigen
induc
high
immun
respons
challeng
cchf
shown
antibodi
direct
np
despit
induct
humor
respons
recent
cchf
vaccin
candid
neither
vaccin
approach
test
efficaci
presum
due
lack
suitabl
anim
model
time
murin
model
suscept
cchf
viru
publish
delet
either
typei
interferon
receptor
knockout
mice
exhibit
signal
defect
respons
major
type
interferon
type
ifna
ifnb
type
ii
ifng
type
iii
ifnl
lead
complet
abolish
intracellular
interferon
respons
efficaci
studi
vaccin
candid
mice
defici
typei
interferon
receptor
use
sinc
less
immun
defici
consid
essenti
test
vaccin
approach
ifng
major
cytokin
involv
adapt
immun
respons
immunogen
mvanp
vaccin
compar
immun
respons
mice
typei
interferon
receptor
defici
parent
wildtyp
strain
differ
observ
either
antibodi
cellmedi
respons
demonstr
knockout
mice
elicit
similar
respons
unsurpris
other
also
report
similar
find
studi
dengu
viru
typei
ifn
receptor
knockout
mice
also
valuabl
studi
efficaci
vaccin
shown
chikungunya
viru
bluetongu
viru
vaccinia
viru
african
hors
sick
viru
therefor
find
cchf
mvanp
vaccin
demonstr
protect
effect
seem
unlik
consequ
anim
model
utilis
present
studi
antibodyinduc
respons
use
western
blot
analysi
use
viru
infect
cell
lysat
recombin
cchf
viral
nucleoprotein
antigen
assess
allow
us
quantifi
antibodi
level
elucid
subclass
immunoglobulin
demonstr
specif
antibodi
recognit
protein
target
due
np
intern
locat
main
effect
viral
immun
lymphocyt
howev
although
recogn
antibodi
viral
np
often
poor
neutralis
other
effect
includ
complementmedi
cytolysi
increas
cell
respons
associ
enhanc
dendrit
cell
function
reduc
viral
replic
cultur
protect
role
cchf
immunoglobulin
current
unknown
although
immun
globulin
therapi
administ
sever
occas
efficaci
still
assess
random
clinic
trial
vaccin
demonstr
protect
effect
work
would
warrant
deciph
immun
respons
deplet
transfer
experi
similarli
tcell
respons
look
ifng
recal
respons
stimul
overlap
peptid
pool
work
identifi
respond
cell
phenotyp
function
cytokinechemokin
secretori
pattern
could
conduct
vaccin
shown
posit
effect
knowledg
first
report
vaccin
cchf
viru
base
nucleoprotein
mvanp
vaccin
candid
demonstr
antigenspecif
immunogen
mice
fail
exert
protect
effect
upon
challeng
cchf
viru
demonstr
lack
immun
correl
protect
vaccin
cchf
viru
need
demonstr
protect
lethal
dose
model
protect
efficaci
establish
cell
cell
american
type
cultur
collect
usa
cultur
modifi
essenti
eagl
medium
sigma
uk
supplement
foetal
bovin
serum
mm
lglutamin
u
penicillin
mgml
streptomycin
sigma
chick
embryon
fibroblast
cef
cell
institut
anim
health
uk
cultur
dulbecco
modifi
eagl
medium
sigma
supplement
cell
european
collect
cell
cultur
uk
maintain
leibovitz
medium
contain
glutamax
life
technolog
uk
supplement
foetal
bovin
serum
sigma
mva
strain
clone
kindli
suppli
prof
b
moss
nih
use
vaccin
construct
viru
titer
determin
plaqu
assay
cell
cchf
viru
strain
prepar
suckl
mous
brain
homogen
titer
determin
tcid
cell
ifnabr
b
k
univers
uk
age
week
use
anim
studi
approv
ethic
review
process
public
health
england
uk
uk
home
offic
via
project
licens
work
involv
anim
perform
accord
unit
kingdom
anim
scientif
procedur
act
plasmid
kindli
provid
prof
b
moss
nih
encod
green
fluoresc
protein
gfp
report
gene
control
promot
express
cassett
control
artifici
promot
allow
constitut
express
heterolog
gene
promot
demonstr
increas
stabil
plasmid
deriv
insert
cassett
cassett
contain
gateway
system
attr
recombin
sequenc
life
technolog
uk
flank
human
tissu
plasminogen
activ
tpa
leader
sequenc
increas
secret
neutralis
antibodi
induct
ctermin
tag
xmal
sali
restrict
site
vitro
immunodetect
np
open
read
frame
segment
cchf
strain
access
number
access
number
use
work
gener
plasmid
pentrnp
respect
plasmid
recombin
pentrnp
use
gateway
technolog
gener
plasmid
ptpnp
result
plasmid
encod
respect
fusion
protein
downstream
poxviru
promot
gener
character
recombin
mva
express
cchfv
nucleoprotein
cell
infect
mva
multipl
infect
infect
cell
transfect
ptpnp
use
lipofectamin
life
technolog
direct
manufactur
result
recombin
mvanp
serial
plaquepurifi
time
cell
base
gfp
express
mvanp
amplifi
cef
cell
purifi
sucros
cushion
centrifug
titrat
plaqu
assay
cell
prior
use
vivo
studi
plaqu
visualis
use
gfp
fluoresc
immunostain
rabbit
antivaccinia
antibodi
abd
serotec
uk
vectastain
univers
abcap
kit
vector
laboratori
usa
genom
dna
infect
cell
extract
use
wizard
sv
genom
dna
purif
system
promega
uk
use
templat
pcr
accuprim
taq
dna
polymeras
high
fidel
life
technolog
uk
qualiti
control
test
ensur
express
insert
protein
confirm
result
western
blot
quantiti
mva
evalu
use
plaqu
assay
cell
group
mice
inject
caudal
aspect
proxim
hindlimb
musculatur
plaqueform
unit
pfu
per
anim
mvanp
dilut
endotoxinfre
pb
total
volum
ml
deliv
equal
across
site
anim
receiv
booster
vaccin
later
control
anim
receiv
pfu
nonrecombin
mva
equival
volum
salin
anim
euthanis
tissu
collect
final
vaccin
interferongamma
ifng
elispot
assay
splenocyt
assess
antigen
recal
respons
via
ifng
elispot
mabtech
sweden
perform
per
manufactur
instruct
cell
seed
pvdf
microtitr
plate
splenocyt
per
well
restimul
peptid
pool
mimotop
australia
overlap
peptid
span
length
cchf
viru
nucleoprotein
consist
offset
residu
appli
final
concentr
mgml
per
peptid
pool
peptid
plate
develop
hour
c
humidifi
incub
supplement
co
spot
count
visual
autom
elispot
reader
autoimmun
diagnostika
gmbh
germani
background
valu
well
contain
medium
peptid
subtract
pool
sum
across
target
protein
result
express
spot
form
unit
sfu
per
cell
antibodi
test
western
blot
cell
monolay
infect
cchf
viru
strain
multipl
infect
moi
approxim
incub
c
leibovitz
medium
contain
foetal
bovin
serum
hour
postinfect
medium
remov
cell
treat
laemmli
buffer
supplement
contain
sodium
dodecyl
sulfat
sd
sigma
result
mixtur
collect
vial
heat
treat
c
minut
use
western
blot
analysi
uninfect
monolay
treat
similarli
use
neg
control
lysat
cchfvinfect
uninfect
cell
subject
sdspage
bistri
gel
life
technolog
transfer
pvdf
membran
block
milk
protein
membran
incub
mous
serum
hour
wash
time
pb
contain
incub
hour
hrpconjug
rabbit
antimous
igg
sigma
goat
antimous
iggam
abd
serotec
wash
antibodi
dilut
made
pb
contain
milk
protein
bound
antibodi
detect
eclprim
wb
detect
reagent
ge
life
scienc
uk
accord
manufactur
direct
visualis
chemidoc
system
biorad
uk
molecular
weight
calcul
comparison
marker
known
molecular
weight
use
quantityon
softwar
fourteen
day
final
vaccin
mvanp
control
substanc
mice
receiv
tcid
cchf
viru
strain
intraderm
midlin
lumbar
region
volum
ml
divid
equal
across
site
ml
maximum
recommend
volum
intraderm
inocul
mice
confirm
intraderm
deliveri
seen
visibl
bleb
format
skin
post
challeng
anim
weigh
bodi
temperatur
measur
daili
subcutan
locat
temperatur
chip
addit
observ
clinic
sign
diseas
twice
daili
arch
ruffl
fur
lethargi
immobl
criteria
euthanasia
welfar
ground
consist
weight
loss
observ
abnorm
clinic
sign
postchalleng
randomli
select
anim
euthanis
sampl
blood
spleen
liver
collect
viral
load
studi
spleen
liver
sampl
also
collect
histopatholog
examin
whole
blood
ml
collect
rna
protect
anim
blood
tube
qiagen
store
c
tube
thaw
invert
left
hour
room
temperatur
ensur
effici
cell
lysi
sampl
treat
red
blood
cell
lysi
solut
miltenyi
biotec
purif
total
rna
use
rneasi
mini
kit
qiagen
viral
load
analysi
spleen
liver
sampl
collect
rnalat
qiagen
store
c
thaw
tissu
transfer
rlt
buffer
qiagen
homogen
pass
mm
siev
treat
use
rneasi
mini
kit
qiagen
extract
total
rna
cchfv
segment
detect
rtpcr
abi
rtpcr
platform
describ
atkinson
et
al
cycl
condit
adjust
describ
quantifast
probe
assay
c
min
c
min
follow
cycl
c
sec
c
sec
quantif
analysi
fluoresc
perform
end
c
step
final
cool
c
sec
synthet
segment
known
concentr
use
quantifi
segment
copi
number
blood
tissu
sampl
reaction
run
triplic
normal
cchfv
express
data
hypoxanthin
guanin
phosphoribosyl
transferas
hprt
housekeep
gene
use
onestep
rtpcr
singleplex
detect
perform
target
bp
product
mous
hprt
gene
ncbi
refer
sequenc
use
quantifast
probe
assay
qiagen
abi
rtpcr
platform
ct
valu
cchfv
hprt
invert
subtract
ct
valu
total
number
cycl
ct
number
cycl
reach
fluoresc
threshold
valu
mean
valu
cchfv
divid
mean
valu
hprt
refer
gene
sampl
sampl
spleen
liver
place
neutral
buffer
formalin
day
process
routin
paraffin
wax
section
cut
mm
stain
haematoxylin
eosin
h
e
examin
microscop
lesion
refer
infect
cchf
viru
score
subject
use
follow
scale
normal
minim
mild
moder
mark
immunohistochemistri
formalinfix
paraffinembed
section
spleen
liver
cut
mm
mount
posit
charg
xtra
adhes
slide
leica
biosystem
uk
deparaffinis
rehydr
immunohistochem
stain
achiev
use
bondmax
immunostain
leica
microsystem
uk
novacastra
bond
intens
r
leica
biosystem
detect
kit
heatinduc
epitop
retriev
cycl
buffer
leica
biosystem
perform
minut
slide
incub
rabbit
serum
abcam
cambridg
uk
minut
follow
avidinbiotin
block
stage
minut
abcam
polyclon
antibodi
rais
sheep
immunis
recombin
cchfv
nucleoprotein
kindli
provid
dr
john
barr
univers
leed
uk
incub
tissu
minut
follow
biotinyl
rabbit
antisheep
polyclon
antibodi
abcam
dilut
minut
haematoxylin
use
counterstain
posit
neg
control
slide
includ
immunolabel
slide
evalu
use
light
microscopi
potenti
conflict
interest
disclos
